J C Thijs

Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study

Loes H.C. Nissen, Lauranne A. A. P. Derikx, A Jacobs, Carla ML van Herpen et autres

Background: Immunosuppressed inflammatory bowel disease (IBD) patients are at increased risk to develop extra-intestinal malignancies. Immunosuppressed transplant patients show increased incidence of head and neck cancer with impaired survival. This study aims to identify risk factors for oral cavity (OCC) and pharyngeal …

nl (code pays fourni par la source)

Small bowel carcinoma mimicking a relapse of Crohn's disease: A case series

Judith E. Baars, J C Thijs, Dirk–Jan Bac, Pieter C. J. ter Borg et autres

We describe three patients diagnosed and treated for presumed (relapsing) Crohn's disease, but who were subsequently diagnosed with a small bowel carcinoma. This case series underlines the necessity of performing a full work up in the diagnosis of CD and to consider …

nl (code pays fourni par la source)

The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis

Edith M.M. Kuiper, Bettina E. Hansen, Wilco Lesterhuis, Rob J. Robijn et autres

nl (code pays fourni par la source)

1097 DYNAMIC UPDATE OF 5- AND 10-YEAR RISK OF LIVER FAILURE OF URSODEOXYCHOLIC ACID-TREATED PATIENTS WITH PRIMARY BILIARY CIRRHOSIS INCLUDING BILIRUBIN AND ALBUMIN OBSERVED DURING FOLLOW-UP

Bettina E. Hansen, Edith M.M. Kuiper, Wilco Lesterhuis, Rob J. Robijn et autres

EntropyMaximization in the Force Network Ensemble for Granular Solids - Authors: Brian P. Tighe, Adrianne R. T. van Eerd, and Thijs J. (TEST GUIDO)

R.P. Adrianne R. T. van Eerd, J C Thijs

[The Nobel Prize in Physiology or Medicine for 2005 for the discovery of the stomach bacterium Helicobacter pylori].

Jan H. Kleibeuker, J C Thijs

This year, the Nobel Prize in Physiology or Medicine was awarded to the Australian doctors Marshall and Warren for their discovery and further identification of the stomach bacterium Helicobacter pylori. Thanks to their confidence in their own observations, we are now able …

nl (code pays fourni par la source)

Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori

Monique M. Gerrits, E.J. van der Wouden, Dorine A. Bax, Anton A. van Zwet et autres

Almost 50 % of all Helicobacter pylori isolates are resistant to metronidazole, which reduces the efficacy of metronidazole-containing regimens, but does not make them completely ineffective. This discrepancy between in vitro metronidazole resistance and treatment outcome may partially be explained by changes …

nl (code pays fourni par la source)

Dyspepsia management in primary care

J C Thijs, Nicolaas L. A. Arents, Anton A. van Zwet, Jan H. Kleibeuker

BACKGROUND: Dyspepsia is common in western society. Prompt endoscopy is imperative in all patients with sinister symptoms or if symptoms first appear after the age of 50-55 years, but the optimal management of younger patients with uncomplicated dyspepsia is still open to …

nl (code pays fourni par la source)

A rational approach to uninvestigated dyspepsia in primary care: review of the literature

Nicolaas L. A. Arents, J C Thijs, Jan H. Kleibeuker

In this paper the rationale and limitations of the four most important approach strategies to dyspepsia in primary care (empiric treatment, prompt endoscopy, "test-and-scope", and "test-and-treat") are analysed. It is concluded that in the absence of alarm symptoms, a "test-and-treat" approach is …

nl (code pays fourni par la source)

Implications of the Simultaneous Presence of Metronidazole-Susceptible and -Resistant Helicobacter pylori Colonies Within a Single Biopsy Specimen

Nicolaas L. A. Arents, Leonard C. Smeets, Anton A. van Zwet, J C Thijs et autres

nl (code pays fourni par la source)

Screening and treating for Helicobacter pylori (“Test-and-treat” strategy) in dyspepsia reduces number of endoscopies with similar clinical outcome as compared to prompt endoscopy

Nicolaas L. A. Arents, J C Thijs, A VANZWET, Jan H. Kleibeuker

Mechanism and Clinical Significance of Metronidazole Resistance in Helicobacter pylori

E J van der Wouden, J C Thijs, JG Kusters, A. A. Van Zwet et autres

Metronidazole was introduced in 1959 for the treatment of Trichomonas vaginalis, but was subsequently shown to be active against anaerobic and some micro-aerophilic bacteria as well. In anaerobic microorganisms with their low redox potential, metronidazole is reduced to its active metabolite by …

nl (code pays fourni par la source)